CymaBay Therapeutics Inc (NASDAQ:CBAY) has been given a consensus recommendation of “Buy” by the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.22.
Several research analysts have recently weighed in on CBAY shares. Zacks Investment Research downgraded shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. ValuEngine raised shares of CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reiterated a “buy” rating on shares of CymaBay Therapeutics in a report on Wednesday, November 6th. Evercore ISI reiterated a “buy” rating and issued a $15.00 price objective on shares of CymaBay Therapeutics in a report on Wednesday, August 14th. Finally, BidaskClub raised shares of CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 23rd.
Shares of NASDAQ:CBAY traded down $0.23 during mid-day trading on Friday, hitting $5.25. 667,677 shares of the company traded hands, compared to its average volume of 852,138. The firm’s 50 day simple moving average is $5.00 and its 200 day simple moving average is $7.14. The firm has a market cap of $372.36 million, a P/E ratio of -4.17 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.12 and a current ratio of 13.12. CymaBay Therapeutics has a 52-week low of $4.23 and a 52-week high of $14.00.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). Equities research analysts expect that CymaBay Therapeutics will post -1.51 EPS for the current fiscal year.
In related news, CEO Sujal Shah purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the chief executive officer now owns 111,900 shares in the company, valued at $618,807. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have bought 11,900 shares of company stock valued at $59,600 in the last three months. Corporate insiders own 4.20% of the company’s stock.
Several hedge funds have recently modified their holdings of CBAY. Bank of Montreal Can grew its stake in CymaBay Therapeutics by 1,372.0% in the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,311 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of CymaBay Therapeutics in the 2nd quarter worth approximately $80,000. Tower Research Capital LLC TRC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter worth approximately $61,000. Aperio Group LLC bought a new stake in shares of CymaBay Therapeutics in the 2nd quarter valued at approximately $104,000. Finally, SG Americas Securities LLC bought a new stake in shares of CymaBay Therapeutics in the 3rd quarter valued at approximately $85,000. 99.49% of the stock is currently owned by institutional investors and hedge funds.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Further Reading: How Do I Invest in Dividend Stocks
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.